Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
DWTX Stock Chart & Stats
$3.15
-$0.11(-4.15%)
At close: 4:00 PM EST
$3.15
-$0.11(-4.15%)
Day’s Range― - ―
52-Week Range$1.87 - $29.28
Previous CloseN/A
Volume14.38K
Average Volume (3M)1.54M
Market Cap
$89.19M
Enterprise Value$96.56M
Total Cash (Recent Filing)$10.13M
Total Debt (Recent Filing)$174.78K
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Apr 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.20
Shares Outstanding32,082,462
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.28K
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$21.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
External Clinical ValidationNational Cancer Institute funding for the planned P1b CIPN study provides third-party validation for the SP16 program and could draw additional support or partnership interest if clinical signals are positive.
Pipeline Expansion Via LicensingAll-stock transaction to secure an exclusive global license for SP16 adds a peptide therapeutic with anti-inflammatory, analgesic, and nerve-repair potential, expanding treatment options for cancer-related pain.
Regulatory PathwayFDA special protocol assessment approval for a Phase 3 registration-directed study of Halneuron in the U.S., Canada, and E.U. strengthens the regulatory pathway toward potential market approval and reduces late-stage trial uncertainty.
Bears Say
Earnings ShortfallNo revenues reported for the quarter and a net loss per share of $8.20 versus consensus of $1.16 represents a significant earnings miss that may pressure the stock and analyst sentiment.
Financing And Dilution RiskAnalyst warns that a cash balance of $10.1M providing runway through 1Q26 increases the likelihood of dilutive equity financing or partner-funded deals under less favorable terms.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.87 and its highest was $29.28 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $89.19M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 77 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Nov 06, 2025. The company reported -$8.2 earnings per share for the quarter, missing the consensus estimate of -$1.16 by -$7.04.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 32,082,462 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$8.2 in its last earnings report, missing expectations of -$1.16. Following the earnings report the stock price went down -6.475%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (566.67% Upside)
$21.00 (566.67% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
-97.54%
Trailing 12-Months
Asset Growth
2559.39%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$21.00
▲(566.67% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
83.23% Insiders
0.11% Mutual Funds
<0.01% Other Institutional Investors
16.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---